Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.


The SENSCIS Trial: Exciting News for Scleroderma-Associated ILD

New Research on Therapies for Patients with Pulmonary Fibrosis

Spring 2019 — What are the Most Exciting Things Happening in Pulmonary Disease?

New Tools to Improve the Diagnosis of IPF vs Other ILDs

Biomarkers in IPF and Other ILDs

Connective Tissue Disease-Related ILD is Now in the Limelight

Patient-Centered Outcomes for Patients with IPF: Activity Monitoring

The Impact of Anticoagulation Use on IPF Patient Outcomes: A Warning About Warfarin

Which Patients with IPF Should be on Antifibrotics? The Value of Shared Decision Making

Dyspnea Assessment in Patients with IPF

Advanced Care Planning and Palliative Care Models for Patients with IPF

Download Audio